KRAS and cancer: This phenotype is concordant with the mutual exclusivity of activating mutations within KRAS and BRAF in patient CRC samples (P < 0.001; Extended Data Fig. 2d), highlighting that the drug addiction phenotype is dependent on pre-existing mutations in the cancer cell.